mRNA Vaccines
Global mRNA Vaccines Market to Reach $127.3 Billion by 2027
Amid the COVID-19 crisis, the global market for mRNA Vaccines estimated at US$64.9 Billion in the year 2021, is projected to reach a revised size of US$127.3 Billion by 2027, growing at a CAGR of 11.9% over the analysis period 2021-2027. COVID-19 Vaccine by Indication, one of the segments analyzed in the report, is forecast to reach US$119 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the cancer vaccine segment is readjusted to a revised 116.7% CAGR for the next 7-year period.
The U.S. Market is Estimated at $29.9 Billion, While China is Forecast to Grow at 17.2% CAGR
mRNA Vaccines market in the U.S. is estimated at US$29.9 Billion in the year 2021. China is forecast to reach a projected market size of US$13.2 Billion by the year 2027 trailing a CAGR of 17.2% over the analysis period 2021 to 2027. Among the other noteworthy geographic markets are Canada, Japan and Europe, each forecast to grow at 11.2% 10% and 10.6% respectively over the 2021-2027 period.
- Arcturus Therapeutics, Inc.
- Argos Therapeutics, Inc.
- BioNTech SE
- CureVac AG
- eTheRNA
- ethris GmbH
- GlaxoSmithKline PLC
- Moderna Therapeutics Inc.
- Pfizer Inc.
- Sangamo Therapeutics Inc.
- Translate Bio Inc.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Impact of Covid-19 and a Looming Global Recession
- The Race Between the Virus & Vaccines Intensifies. Amidst this Chaotic Battle, Where Is The World Economy Headed in 2021?
- Increased Hospital Admissions and Deaths Characterize Second and Third Wave
- EXHIBIT 1: Daily New Confirmed Cases (Per Million) by Select Country
- With IMF’s Upward Revision of Global GDP Forecasts for 2021, Most Companies Are Bullish about a Global Economic Comeback.
- EXHIBIT 2: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
- Unprecedented Crisis Prompts Biden Administration to Support Efforts to Waive Intellectual Property Rights for COVID-19 Vaccines
- EU Joins US in Quest to Waive COVID-19 Vaccine Patent Protections
- mRNA - A CONCEPTUAL UNDERSTANDING
- mRNA: A New Approach to Medicine
- Long Wait & Scientific Breakthroughs
- mRNA Vaccines - An Introduction
- mRNA Vaccine Approvals
- A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
- Traditional Vs. mRNA Vaccines: Key Differences
- Traditional Vs. mRNA Vaccines: The Development Process
- How mRNA Vaccine Works & Earlier Testing Efforts
- mRNA Vaccines: Safety Quotient
- Other Notable Efforts Centered on mRNA Technology
- Overcoming Challenges
- As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community
- GLOBAL MARKET OVERVIEW
- Global mRNA Platform Market Set for a Stupendous Growth in Future
- Riding COVID-19 Wave, mRNA Vaccines Take Center Stage & See Exciting Times Ahead
- COVID-19 mRNA Vaccine Approval Details
- COVID-19 Funding Details of Moderna,Pfizer, and CureVac Vaccine
- EXHIBIT 3: Production Capacity of mRNA Frontrunners in Millions of Doses for 2021
- COVID-19 Pandemic: An Eventful Year for RNA
- EXHIBIT 4: COVID-19 Cases Worldwide by Country: As on May 17, 2021
- COVID-19’s Impact on Vaccine Development – A Transformative Shift to mRNA vaccines
- mRNA Based Vaccines in Clinical Development
- EXHIBIT 5: Vaccines in Human Trials by Technology
- EXHIBIT 6: Vaccine Technologies in Pre-Clinical Studies
- Battling the COVID-19 Pandemic: The Global Fight Extends Longer as Variants Emerge Stronger
- COVID-19 Virus Can Adapt & Undergo ‘Escape Mutation’ to Pose Vaccine Challenge
- Indian Variant of COVID-19 Virus Puts Healthcare System on Brink of Major Collapse
- Investigating the Virulence Profile of India’s N440K Variant
- Is South African Variant a Formidable Threat?
- E484K Mutation Challenges Vaccine Developers
- Rising Cases in South Africa & Other Countries
- California Strain Emerges to be More Contagious and Deadly
- Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant
- Pfizer/BioNTech Trailing a Third Covid-19 Shot to Provide Variant Protection
- Moderna’s Variant-Specific Vaccine Candidate Ready for Clinical Study
- mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market
- The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market
- Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations
- The East Falls behind the West in Embracing the Revolutionary mRNA Technology for Developing Vaccines to Fight against COVID-19
- RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE
- Pfizer and BioNTech’s COVID-19 Vaccine Receives World’s First Authorization
- UK Clinches the First Position in the World to Approve Pfizer’s Vaccine
- After UK, US Gives Nod to Pfizer’s Vaccine
- EU Approves Pfizer’s Vaccine
- BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
- Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production
- FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
- Moderna’s mRNA Vaccine Bags Approval from US FDA
- Moderna Kick-Starts Inoculation in the US
- FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
- Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
- Recent Market Activity
- COMPETITIVE SCENARIO
- BioNTech – A Pioneer in mRNA-based Vaccines and Therapies
- List of BioNTech’s mRNA Candidates in Clinical Trials for Cancer
- Moderna’s Ambitious Stride into Vaccine Development: From a Novice to Know All
- Moderna’s mRNA Prophylactic Vaccines
- mRNA Cancer Vaccines
- mRNA Intratumoral Immuno-Oncology
- mRNA Systemic Secreted & Cell Surface Therapeutics
- mRNA Systemic Intracellular Therapeutics
- Sanofi Commences Clinical Trials of mRNA vaccine for Covid-19
- mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon
- Noteworthy Startups Exploiting mRNA Technology
- Providence Therapeutics
- pHion Therapeutics
- eTheRNA immunotherapies & 20Med Therapeutics
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Incidence of Coronavirus Cases Drive the Market Demand
- Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead
- mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum
- EXHIBIT 7: Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
- EXHIBIT 8: Global HIV Prevalence: Number of People Living with AIDs (in Thousands) by Region for 2018
- EXHIBIT 9: Number of AIDS-Related Deaths (in Thousands) by Region for 2018
- Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
- EXHIBIT 10: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
- EXHIBIT 11: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
- Increasing Healthcare Expenditure to Foster Market Growth
- EXHIBIT 12: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
- EXHIBIT 13: Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
- Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
- EXHIBIT 14: Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
- Regulatory Landscape for mRNA Vaccines
- Regulatory Pathway Dealing with mRNA Vaccines
- mRNA Vaccine Patent Scenario
- The Best Route of Administration for mRNA Vaccines
- CDC Study on Vaccine Effectiveness States mRNA Vaccines Offer More Protective Benefits than other Vaccines (March, 2021)
- mRNA CANCER VACCINES
- Introduction
- Cancer Vaccines Vs. Immunotherapies
- Clinical Trials of mRNA Encoding Immunostimulants
- mRNA Vaccines Vs. DNA Vaccines
- Clinical Trials of mRNA Encoding TAAs
- mRNA Vaccines Vs. Other Vaccines
- Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag)
- mRNA Benefits Profile
- mRNA Vaccines for Covid-19 Pave the Way
- Challenges
- Personalized mRNA Vaccine
- Clinical Overview of mRNA Cancer Vaccines
- mRNA encoding Immunostimulants
- mRNA vaccine encoding tumor-associated antigens
- mRNA vaccine encoding Neoantigen, personalized vaccine
- MRNA INFLUENZA VACCINES
- Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform
- Vaccines Built on mRNA
- Clinical Trials for mRNA Vaccines
- mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts
- mRNA: A Next-Generation Vaccination Approach
- Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses
- COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots
- mRNA Vaccines Vs. Other Flu Shots
- mRNA Technology, H/N Spike Proteins & Clinical Trials
- mRNA Technology: A Suitable Candidate for Universal & Effective Influenza Vaccines
- Benefits & Limitations of mRNA Vaccines over Traditional Options
- Benefits
- Limitations
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Current & Future Analysis for mRNA Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
- TABLE 2: World 6-Year Perspective for mRNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027
- TABLE 3: World Current & Future Analysis for COVID-19 mRNA Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
- TABLE 4: World 6-Year Perspective for Covid-19 mRNA Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
- TABLE 5: World Current & Future Analysis for mRNA Cancer Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
- TABLE 6: World 6-Year Perspective for mRNA Cancer Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
- TABLE 7: World Current & Future Analysis for Other mRNA Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
- TABLE 8: World 6-Year Perspective for Other mRNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
- III. MARKET ANALYSIS
- UNITED STATES
- US FDA Gives Nod to Pfizer and Moderna’s mRNA Vaccines
- Moderna to Supply 100 Million more Doses of COVID-19 Vaccine to the US Government
- Lonza Announces Plans to Double Moderna COVID-19 Vaccine Output in Switzerland
- US Regulators Give Nod to Pfizer-BioNTech COVID-19 Vaccine for Ages 12 to 15
- Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines for Global Supply
- Market Analytics
- TABLE 9: USA Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 10: USA 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- CANADA
- Vaccination Gathers Steam Across Canada
- EXHIBIT 15: Percentage (%) of Population Vaccinated (at least one dose) in Canada by Province/Territory As of May 3, 2021
- COVID-19 Vaccine Deals in Canada
- Pfizer Plans to Ramp up COVID-19 Vaccine Supply to Canada from May, 2021
- Canada Grants Approval to Pfizer’s COVID-19 Shot for Use in Children in 12-15 Years Age Group
- Market Analytics
- TABLE 11: Canada Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 12: Canada 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- JAPAN
- COVID-19 Vaccination Programs in Japan Move Forward at Snail’s Pace
- Reasons Responsible for Setback
- Vaccine Timeline & Availability
- Japan Demands for Vaccine-Related Data
- People’s Low Trust in Vaccines
- Japan’s Efforts to Develop Indigenous Vaccines
- Japan to Step Up COVID-19 Immunization Drive to Cover Geriatric Population
- Japan Inks Deal with Pfizer to Secure 50 Million Additional Doses of COVID-19 Vaccine
- Japan Pushes Shipments of Pfizer’s COVID-19 Shots to Vaccinate Elderly
- Market Analytics
- TABLE 13: Japan Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 14: Japan 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- CHINA
- BioNTech’s Shot to Become First Western COVID-19 Vaccine to Secure Authorization in China
- Market Analytics
- TABLE 15: China Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 16: China 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- EUROPE
- EU Urges Nations to Focus on COVID-19 Vaccine Sharing & Export to Beat the Pandemic (May, 2021)
- COVID-19 Vaccine Drive Gathers Pace in Europe after Initial Glitch
- EU Approves Pfizer’s Vaccine
- EU Eyes on Milestone Deal to Get 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
- European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines
- BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
- Market Analytics
- TABLE 17: Europe Current & Future Analysis for mRNA Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
- TABLE 18: Europe 6-Year Perspective for mRNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027
- TABLE 19: Europe Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 20: Europe 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- FRANCE
- TABLE 21: France Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 22: France 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- GERMANY
- TABLE 23: Germany Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 24: Germany 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- ITALY
- Italy Plans to Produce mRNA Vaccines Domestically
- Market Analytics
- TABLE 25: Italy Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 26: Italy 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- UNITED KINGDOM
- Market Analysis
- UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech Vaccine
- Moderna Modifies Supply Contract with UK to Deliver Additional Doses of COVID-19 Vaccine
- UK’s Independent Vaccine Deals
- Market Analytics
- TABLE 27: UK Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 28: UK 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- REST OF EUROPE
- TABLE 29: Rest of Europe Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 30: Rest of Europe 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- ASIA-PACIFIC
- INDIA
- Pfizer Looks Forward to Make its COVID-19 Vaccine Available in India
- AUSTRALIA
- Australia to Buy 20 Million Extra Doses of Pfizer COVID-19 Vaccine, Pivoting away from AstraZeneca
- NEW ZEALAND
- New Zealand Acquires Ultra-Cold Freezers to Store Pfizer’s COVID-19 Vaccine
- Market Analytics
- TABLE 31: Asia-Pacific Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 32: Asia-Pacific 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- REST OF WORLD
- THE MIDDLE EAST
- BAHRAIN
- Bahrain Becomes the Second Country to Offer Emergency Use Approval to Pfizer’s Vaccine
- AFRICA
- SOUTH AFRICA
- New Virus Variant in South Africa Creates a Challenge
- Highly Infectious COVID-19 Variant Spurs Countries to Impose Travel Ban from South Africa
- LATIN AMERICA
- Mass COVID-19 Vaccination Campaigns Launched in Latin American Countries
- BRAZIL
- Brazil Signs Deal to Buy Additional 100 Million Doses from Pfizer/BioNTech
- MEXICO
- Mexico’s Cofepris Approves Emergency Use of Pfizer's COVID-19 Vaccine
- Market Analytics
- TABLE 33: Rest of World Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
- TABLE 34: Rest of World 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
- IV. COMPETITION
- Total Companies Profiled: 92
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook